The Cancer Immunology (CI) Program at the Hollings Cancer Center (HCC) seeks to uncover how the immune system recognizes and kills tumors and to use this information to develop effective immuno-oncology (IO) strategies to treat patients. Three unifying themes promote these goals: 1) immunotherapy; 2) inflammation and tolerance; and 3) T-cell biology. Notable progress has been made in all three areas. This includes launch and completion of the first phase 1b/2 trial on the treatment of advanced non-small cell lung cancer using the combination of a PD-1 antagonist and super-agonist recombinant IL-15, developing novel oncolytics that block the PD-1 pathway, a first report elucidating how platelets blunt T-cell immunity via the GARP-TGF? axis, eluci- dating the roles of CD38 in generating the anti-tumor hybrid Th1/17 cells, uncovering the mechanism that sus- tains cytokine signaling, and discovering highly potent human CD26+ lymphocytes for cell therapy of cancer. The program is co-led by two exceptional immunologists with distinct basic and clinical backgrounds who col- laboratively build a synergistic program conducting cutting edge research: Zihai Li, MD, PhD is a board-certi- fied medical oncologist and immunologist with expertise in inflammation and tolerance; Chrystal Paulos, PhD is a tumor immunologist with expertise in basic T-cell biology and adoptive T-cell transfer therapy. There are 20 program members from seven academic departments. The annual funding base is $4.4 million in direct costs, excluding career development and training grants. There are 28 active cancer-related funded projects, nine from the NCI, including a new multi-institutional program project (NCI P01 CA186866). In the current cycle, CI members published 138 peer-reviewed papers, of which 40% are intra- and 43% interprogrammatic collabora- tions. The exceptional impact of the program?s research is highlighted by 20 publications in journals with an impact factor >10 including Cancer Discov, Cell Metab, Sci Transl Med, J Clin Invest, Nat Med (2018), Nat Commun, Nat Struct Mol Biol, and Lancet Oncol (2018). Since the last renewal, the HCC contributed funding to recruit seven new CI members, including one senior clinician-scientist (Raymond DuBois, MD, PhD). Their re- cruitment fostered new investigator-initiated clinical trials and provided big data analysis expertise. HCC also supported a number of events, including inter-programmatic joint spring symposia and multi-institutional re- treats. The program benefits from all HCC shared resources, particularly the Biostatistics and Flow Cytometry & Cell Sorting Shared Resources, which added a 2nd-generation mass cytometer for high-dimensional single- cell analysis, reflecting a significant institutional investment. With the maturation of the CI Program into a syn- ergistic team of multidisciplinary investigators, the rapid progress of IO, strong support from the new HCC lead- ership, and the key shift in the field toward harnessing the immune system to treat cancer, the CI Program is positioned for robust progress in all thematic research areas in the next funding cycle.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA138313-11
Application #
9701572
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-04-01
Budget End
2020-03-31
Support Year
11
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Medical University of South Carolina
Department
Type
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29403
Welch, Brandon M; Wiley, Kevin; Pflieger, Lance et al. (2018) Review and Comparison of Electronic Patient-Facing Family Health History Tools. J Genet Couns 27:381-391
Luque, John S; Tarasenko, Yelena N; Li, Hong et al. (2018) Utilization of Cervical Cancer Screening Among Hispanic Immigrant Women in Coastal South Carolina. J Racial Ethn Health Disparities 5:588-597
Panganiban, Clarisse H; Barth, Jeremy L; Darbelli, Lama et al. (2018) Noise-induced dysregulation of Quaking RNA binding proteins contributes to auditory nerve demyelination and hearing loss. J Neurosci :
Furukawa, Brian S; Pastis, Nicholas J; Tanner, Nichole T et al. (2018) Comparing Pulmonary Nodule Location During Electromagnetic Bronchoscopy With Predicted Location on the Basis of Two Virtual Airway Maps at Different Phases of Respiration. Chest 153:181-186
Vila├ža, Rita; Barros, Ivo; Matmati, Nabil et al. (2018) The ceramide activated protein phosphatase Sit4 impairs sphingolipid dynamics, mitochondrial function and lifespan in a yeast model of Niemann-Pick type C1. Biochim Biophys Acta Mol Basis Dis 1864:79-88
Pandey, Janardan P; Namboodiri, Aryan M; Armeson, Kent E et al. (2018) IGHG, IGKC, and FCGR genes and endogenous antibody responses to GARP in patients with breast cancer and matched controls. Hum Immunol 79:632-637
Mulligan, Jennifer K; Patel, Kunal; Williamson, Tucker et al. (2018) C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis. Mucosal Immunol 11:1375-1385
Zhu, Yun; Wang, Cindy; Becker, Scott A et al. (2018) miR-145 Antagonizes SNAI1-Mediated Stemness and Radiation Resistance in Colorectal Cancer. Mol Ther 26:744-754
Tomko, Rachel L; Gray, Kevin M; Oppenheimer, Stephanie R et al. (2018) Using REDCap for ambulatory assessment: Implementation in a clinical trial for smoking cessation to augment in-person data collection. Am J Drug Alcohol Abuse :1-16
Wolfe, A M; Dunlap, K M; Smith, A C et al. (2018) Myxoma Virus M083 Is a Virulence Factor Which Mediates Systemic Dissemination. J Virol 92:

Showing the most recent 10 out of 536 publications